Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57. Following the sale, the chief accounting officer owned 15,000 shares in the company, valued at $543,150. This represents a 83.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $34.74 on Wednesday. The firm’s 50-day moving average price is $37.00 and its 200-day moving average price is $29.23. The company has a market capitalization of $3.94 billion, a PE ratio of -16.95 and a beta of 0.05. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. Equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. PTM Wealth Management LLC bought a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at $256,000. Knights of Columbus Asset Advisors LLC bought a new stake in NewAmsterdam Pharma during the second quarter valued at about $595,000. Franklin Resources Inc. grew its holdings in NewAmsterdam Pharma by 30.6% during the second quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after purchasing an additional 78,300 shares during the period. Frazier Life Sciences Management L.P. raised its stake in shares of NewAmsterdam Pharma by 3.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after buying an additional 490,656 shares during the period. Finally, Trexquant Investment LP purchased a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at about $1,353,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NAMS shares. Stifel Nicolaus lifted their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. Citigroup increased their price target on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. The Goldman Sachs Group raised their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. Finally, Needham & Company LLC upped their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $45.90.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.